{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD-1+Checkpoint+Inhibitor&page=2", "query": { "intervention": "Anti-PD-1 Checkpoint Inhibitor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-PD-1+Checkpoint+Inhibitor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T04:07:48.228Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05733598", "title": "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "RP2", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "RP2 Monotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-08-01", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 12, "location_summary": "Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733598" }, { "nct_id": "NCT04068181", "title": "Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 72, "start_date": "2020-01-22", "completion_date": "2024-02-26", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 10, "location_summary": "Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Fridley", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068181" }, { "nct_id": "NCT04020185", "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "IMSA101", "type": "DRUG" }, { "name": "Immune checkpoint inhibitor (ICI)", "type": "DRUG" }, { "name": "Immuno-oncology (IO) therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmuneSensor Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-09-23", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020185" }, { "nct_id": "NCT01656642", "title": "A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-08-13", "completion_date": "2020-03-25", "has_results": false, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656642" }, { "nct_id": "NCT01940809", "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF V600E Mutation Present", "BRAF V600K Mutation Present", "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-08-28", "completion_date": "2022-03-04", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940809" }, { "nct_id": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GAd-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "GAd-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "GAd20-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nouscom SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-10-21", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041310" }, { "nct_id": "NCT03493932", "title": "Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "BMS-986016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-09-24", "completion_date": "2023-06-27", "has_results": true, "last_update_posted_date": "2024-07-24", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Bethesda, Maryland", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493932" }, { "nct_id": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells", "type": "BIOLOGICAL" }, { "name": "PD1 Inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-07-19", "completion_date": "2022-08-16", "has_results": true, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639245" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT05332925", "title": "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "NSCLC", "NSCLC Stage IV" ], "interventions": [ { "name": "Standard of care immune checkpoint inhbitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 25, "start_date": "2022-07-21", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-09-28T04:07:48.228Z", "location_count": 2, "location_summary": "Fairway, Kansas • Kansas City, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332925" } ] }